Cisbio Introduces IP-One ELISA at 4th Annual GPCR Congress
Friday, May 26, 2006
Cisbio international has announced the release of its second IP-One assay, IP-One ELISA, at the 4th Annual GPCR Congress in Barcelona, Spain.
This assay development tool complements Cisbio’s existing IP-One HTRF® assay to create a portfolio of fundamental assays for IP1 (inositol(1)phosphate) quantification and GPCR screening accessible to all laboratories.
IP-One ELISA is a monoclonal antibody-based assay that can detect IP1, one of the major products of the phosphatidyl inositol cascade, which tightly correlates with Gq-coupled activity.
IP-One ELISA is designed to deliver second messenger measurement and represents a way of investigating molecular events occurring at the membrane level.
This kit is an adaptation of Cisbio’s IP-One HTRF® assay, a high throughput screening method based on Cisbio’s proprietary HTRF® technology and which was launched last year, to the ELISA detection method.
For Cisbio’s existing customers that currently deploy HTRF® assays, there is a transition to running the IP-One HTRF® assay that involves no further capital investment in equipment or technologies.
Cisbio recognized the need to adapt its IP-One technology into a universal method which larger audiences who are not equipped with an HTRF® compatible reader could use as well, and developed IP-One ELISA with academic laboratories in mind.
"Cisbio international continues its commitment to R&D; innovation in the field of GPCR screening, and IP-One ELISA is yet another example of this initiative," said François Degorce, head of HTRF® marketing & business development, Cisbio international.
"It was important for us to enable a larger customer base, whose resources might not allow for investment in compatible laboratory equipment, to also benefit from IP-One technology."
The IP-One ELISA kit contains all the components necessary to perform 96 or 480 tests, and is able to measure small levels of IP1 concentration.
Performance wise, IP-One ELISA is rapid, sensitive (EC50: 150 nM, detection limit is 10 nM), and there is no cross-reactivity with 50 µM myo-inositol, PIP2, IP2, IP3, IP4 or PIP3.
Cells are plated in the appropriate cell culture plate and stimulated by a drug of interest; then, after lysis, the supernatant is transferred into the ELISA plate and the IP1 produced is detected by addition of the ELISA reagents.
Over 50 GPCR targets have already been validated with Cisbio’s IP-One assays, reconfirming the relevance of IP1 as a new secondary messenger of Gq-Protein Coupled Receptors.